Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Atara Biotherapeutics (ATRA) Profit After Tax (2022 - 2025)

Atara Biotherapeutics' Profit After Tax history spans 4 years, with the latest figure at -$3.4 million for Q4 2025.

  • For Q4 2025, Profit After Tax rose 73.17% year-over-year to -$3.4 million; the TTM value through Dec 2025 reached $32.7 million, up 138.28%, while the annual FY2025 figure was $32.7 million, 138.28% up from the prior year.
  • Profit After Tax reached -$3.4 million in Q4 2025 per ATRA's latest filing, up from -$4.3 million in the prior quarter.
  • In the past five years, Profit After Tax ranged from a high of $38.0 million in Q1 2025 to a low of -$88.1 million in Q1 2022.
  • Average Profit After Tax over 4 years is -$34.8 million, with a median of -$26.8 million recorded in 2024.
  • Peak YoY movement for Profit After Tax: tumbled 485.08% in 2023, then surged 219.71% in 2025.
  • A 4-year view of Profit After Tax shows it stood at -$74.6 million in 2022, then increased by 18.94% to -$60.4 million in 2023, then soared by 79.0% to -$12.7 million in 2024, then soared by 73.17% to -$3.4 million in 2025.
  • Per Business Quant, the three most recent readings for ATRA's Profit After Tax are -$3.4 million (Q4 2025), -$4.3 million (Q3 2025), and $2.4 million (Q2 2025).